Peptide in 60 Seconds
Retatrutide, Explained in 60 Seconds: One Peptide, Three Hormone Targets
The investigational "triple agonist" posted some of the largest average weight reductions ever reported in an obesity trial — in Phase 2. Here's what that does and doesn't mean.
Evidence strength
Strength of human clinical evidence — A (strongest) to D (mostly preclinical). This reflects research maturity, not safety or suitability.
Vial Theory provides educational research summaries only. Content is not medical advice, diagnosis, treatment, dosing guidance, or individualized suitability screening. Regulatory status can change over time and varies by jurisdiction.
Key Takeaways
- ›Retatrutide is an investigational triple agonist — GIP + GLP-1 + glucagon receptors — given once weekly in trials.
- ›Phase 2 trials reported some of the largest average weight reductions seen in obesity research (Jastreboff et al., NEJM, 2023; 338 adults, 48 weeks).
- ›A parallel Phase 2 trial reported reduced HbA1c and body weight in type 2 diabetes (Rosenstock et al., The Lancet, 2023).
- ›Grade B = research maturity, not safety: Phase 2 only, small samples, under a year of follow-up, no head-to-head data.
- ›It is not approved anywhere; Phase 3 (TRIUMPH) is ongoing across obesity, diabetes, MASH, and osteoarthritis.
- ›Gastrointestinal effects and increased heart rate were reported; long-term cardiovascular safety is not established.
The Brief
Semaglutide activates one metabolic receptor. Tirzepatide activates two. Retatrutide — Eli Lilly's investigational peptide, also known as LY3437943 — activates three at once: GIP, GLP-1, and the glucagon receptor. That third target is the whole story, and it is why this compound dominates so much of the current conversation around next-generation obesity drugs.
In the pivotal Phase 2 obesity trial, published in the New England Journal of Medicine in 2023, retatrutide produced dose-dependent body-weight reductions over 48 weeks that substantially exceeded placebo — some of the largest mean reductions observed in any obesity trial program to date. A parallel Phase 2 trial in type 2 diabetes, published the same year in The Lancet, reported reductions in both HbA1c and body weight.
So why do we grade it B — "Early but Meaningful Human Evidence" — and not A? Because everything above comes from Phase 2: a few hundred participants, under a year of follow-up, and no published head-to-head comparison against the drugs it's meant to surpass. The gap between a stunning Phase 2 readout and an established result is exactly where this story gets interesting.
Read the full brief with Vial+
You’ve read the opening. Vial+ unlocks the full evidence breakdown and 3 cited sources — plus every full research report, all graphs, and the complete archive of weekly briefs.
Get Vial+ — $20 one-timeLifetime access · the community forum stays free.
Disclaimer: This content is for educational and research purposes only and is not medical advice. Evidence grades describe research maturity, not safety or suitability. Always consult a licensed healthcare professional before making health-related decisions.